40335-00-0

Usage

Uses

Used in Organic Chemistry:
2,4-diMethoxyquinoline is used as a borylation ligand for promoting direct borylation of C(sp3)-H bonds. This application is particularly useful in the synthesis of complex organic molecules and pharmaceuticals, as it allows for the selective introduction of boron-containing functional groups into target molecules.
Used in Pharmaceutical Synthesis:
2,4-diMethoxyquinoline is used as a key intermediate in the synthesis of various pharmaceutical compounds. Its ability to facilitate borylation reactions enables the development of new drugs with improved properties, such as enhanced bioavailability and targeted delivery.
Used in Material Science:
2,4-diMethoxyquinoline can be employed in the development of novel materials with specific properties, such as improved thermal stability or electrical conductivity. By incorporating boron-containing functional groups into the molecular structure, new materials with tailored characteristics can be created for various applications.

InChI:InChI=1/C11H11NO2/c1-13-10-7-11(14-2)12-9-6-4-3-5-8(9)10/h3-7H,1-2H3

Upstream product

• 67-56-1 methanol 
• 124-41-4 sodium methylate 
• 703-61-7 2,4-dichloroquinoline 
• 27667-34-1 4-methoxyquinolin-2(1H)-one 
• 74-88-4 methyl iodide 
• 70254-43-2 4-Hydroxy-2-quinolone 

Downstream Products

• 484-29-7 dictamnine 
• 868860-38-2 2,4-Dimethoxy-3-phenyl-quinoline 

Relevant academic research and scientific papers

Compositions for Treatment of Cystic Fibrosis and Other Chronic Diseases

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Euodenine A: A small-molecule agonist of human TLR4

A small-molecule natural product, euodenine A (1), was identified as an agonist of the human TLR4 receptor. Euodenine A was isolated from the leaves of Euodia asteridula (Rutaceae) found in Papua New Guinea and has an unusual U-shaped structure. It was synthesized along with a series of analogues that exhibit potent and selective agonism of the TLR4 receptor. SAR development around the cyclobutane ring resulted in a 10-fold increase in potency. The natural product demonstrated an extracellular site of action, which requires the extracellular domain of TLR4 to stimulate a NF-κB reporter response. 1 is a human-selective agonist that is CD14-independent, and it requires both TLR4 and MD-2 for full efficacy. Testing for immunomodulation in PBMC cells shows the induction of the cytokines IL-8, IL-10, TNF-α, and IL-12p40 as well as suppression of IL-5 from activated PBMCs, indicating that compounds like 1 could modulate the Th2 immune response without causing lung damage.

MODULATORS OF ATP-BINDING CASSETTE TRANSPORTERS

The present invention relates to modulators of ATP-Binding Cassette (“ABC”) transporters or fragments thereof, including Cystic Fibrosis Transmembrane Conductance Regulator, compositions thereof, and methods therewith. The present invention also relates to methods of treating ABC transporter mediated diseases using such modulators.

Synthesis and characterization of substituted 4-methoxy-1H-quinolin-2- thiones

The synthesis of various substituted 4-methoxy-1H-quinolin-2-thiones from various substituted aniline with malonic acid, phosphorousoxychloride, sodium methoxide glacial acetic acid and thiourea under different conditions is described. All these substituted 4-methoxy-1H-quinolin-2-thiones were synthesized from four steps; the first step involved the synthesis of substituted 2,4-dichloro quinoline from aniline (substituted), with malonic acid and phosphorous-oxychloride. In the second step, the substituted 2,4-dichloro compound was heated with freshly prepared methanolic sodium methoxide solution to give 2,4-dimethoxy quinoline compounds, it was then refluxed with glacial acetic acid and hydrochloric acid to get the substituted 4-methoxy-1H-quinolin- 2-one. The final steps involves with an objective of introducing a chloro in the position 2 of the quinolone system, the substituted 4-methoxy-1H-quinolin-2-one was refluxed with distilled PoCl3 chloroform. The substituted 2-chloro-4-methoxy quinoline was then refluxed with thiourea and alcohol to get substituted 4-methoxy-1H-quinolin-2-thiones. The purity of the synthesized compound was judged by their C, H and N analysis and the structure was analyzed on the basics of mass, FT-IR and 1H NMR.

COMPOSITIONS FOR TREATMENT OF CYSTIC FIBROSIS AND OTHER CHRONIC DISEASES

The present invention relates to pharmaceutical compositions comprising an inhibitor of epithelial sodium channel activity in combination with at least one ABC Transporter modulator compound of Formula A, Formula B, Formula C, or Formula D. The invention also relates to pharmaceutical formulations thereof, and to methods of using such compositions in the treatment of CFTR mediated diseases, particularly cystic fibrosis using the pharmaceutical combination compositions.

Synthesis and characterization of substituted 4-methoxy-1H-quinolin-2-ones

An efficient method for the synthesis of various substituted 4- methoxy-1H-quinolin-2-ones from various substituted aniline with malonic acid, phosphorous oxychloride, sodium methoxide and glacial acetic acid under different conditions is described. The title compounds were synthesized from three steps; the first step involved the synthesis of substituted 2, 4-dichloro quinoline from aniline (substituted), with malonic acid and phosphorousoxychloride. In the second step, the substituted 2, 4 dichloro compounds was heated with freshly prepared methanolic sodium methoxide solution to give 2, 4-dimethoxy quinoline compounds, it was then refluxed with glacial acetic acid and hydrochloric acid to give the titled compounds in the final step. The purity of the synthesized compounds was confirmed by their C, H and N analysis and the structure was analyzed on the basics of Mass, FT-IR and 1H NMR.

Demethylation of 2,4-dimethoxyquinolines: the synthesis of atanine.

The synthesis of the quinoline alkaloid atanine 6, by selective demethylation of the 2,4-dimethoxyquinoline 11 is presented. An alternative demethylation utilising a thiolate anion leads to the regioisomeric 4-hydroxyquinoline 13.

Further studies of regioselective alkoxydehalogenation of 2,4-dichloroquinolines, 2,6-dichloropyridine and 2,4-dichloronitrobenzene

Regioselective alkoxydehalogenation reactions using solid alkoxide in toluene have been studied. 2-Alkoxy-4-haloquinolines were obtained from 2,4-dichloroquinolines. With 2,6-dichloropyridine, α-regioselectivity occurred to furnish the 2-alkoxy-6-chloropyridine. The reaction failed with 2,4-dichloronitrobenzene indicating that alkoxide surface contact with a basic heterocyclic nitrogen lone pair was essential for success. Comparative studies with the standard alkoxydehalogenation reaction (alcoholic alkoxide solution) have been performed, all compounds have been identified by 1H and 13C NMR.

Methylation of 4-Hydroxy-2-quinolone

The reaction of 4-hydroxy-2-quinolone (1a) with methyl iodide/potassium hydroxide in boiling acetone gave a mixture of 1-methyl-4-methoxy-2-quinolone (1d), 1,3-dimethyl-4-methoxy-2-quinolone (1e), and 1,3,3-trimethyl-2,4-dioxo-1,2,3,4-tetrahydroquinoline (2).As by-product 2,4-dimethoxyquinoline (3) was identified.Under the same conditions 4-methoxy-2-quinolone (1c) yielded 1d, 1e, 2 and 3, while 1-methyl-4-hydroxy-2-quinolone (1b) gave 1d, 1e and 2.